Literature DB >> 8666998

Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients.

G P Lim1, J R Backstrom, M J Cullen, C A Miller, R D Atkinson, Z A Tökés.   

Abstract

Matrix metalloproteinases (MMPs) were analyzed by immunohistochemistry and zymography in amyotrophic lateral sclerosis (ALS) and control brain and spinal cord specimens. Three major bands of enzyme activity (70, 100, and 130 kDa) were consistently observed and were subsequently identified as MMP-2 (70 kDa; also known as EC 3.4.24.24 or gelatinase A) and MMP-9 (100 and 130 kDa; also known as EC 3.4.24.35 or gelatinase B). Immunohistochemical studies established the presence of MMP-2 in astrocytes and MMP-9 in pyramidal neurons in the motor cortex and motor neurons in the spinal cord of ALS patients. Although a significant decrease in MMP-2 activity was noticed in the ALS motor cortex, statistically significant increases in MMP-9 (100-kDa) activity were observed in ALS frontal and occipital cortices (BA10 and 17) and all three spinal cord regions when compared with control specimens. The highest MMP-9 (100-kDa) activities in ALS were found in the motor cortex and thoracic and lumbar cord specimens. The abnormally high amount of MMP-9 and its possible release at the synapse may destroy the structural integrity of the surrounding matrix, thereby contributing to the pathogenesis of ALS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666998     DOI: 10.1046/j.1471-4159.1996.67010251.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  30 in total

1.  Role of matrix metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place preference.

Authors:  Travis E Brown; Melissa R Forquer; Davelle L Cocking; Heiko T Jansen; Joseph W Harding; Barbara A Sorg
Journal:  Learn Mem       Date:  2007-03-09       Impact factor: 2.460

2.  Metalloproteinase alterations in the bone marrow of ALS patients.

Authors:  Patrizia Bossolasco; Lidia Cova; Cinzia Calzarossa; Federica Servida; Niccolò Emanuele Mencacci; Francesco Onida; Elio Polli; Giorgio Lambertenghi Deliliers; Vincenzo Silani
Journal:  J Mol Med (Berl)       Date:  2010-01-21       Impact factor: 4.599

3.  Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus.

Authors:  Arek Szklarczyk; Joanna Lapinska; Marcin Rylski; Ronald D G McKay; Leszek Kaczmarek
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

Review 4.  Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders.

Authors:  Santiago Rivera; Laura García-González; Michel Khrestchatisky; Kévin Baranger
Journal:  Cell Mol Life Sci       Date:  2019-06-13       Impact factor: 9.261

5.  Hereditary diffuse leukoencephalopathy with spheroids: ultrastructural and immunoelectron microscopic studies.

Authors:  Wen-Lang Lin; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Int J Clin Exp Pathol       Date:  2010-07-26

6.  Morbillivirus infection of the mouse central nervous system induces region-specific upregulation of MMPs and TIMPs correlated to inflammatory cytokine expression.

Authors:  S T Khuth; H Akaoka; A Pagenstecher; O Verlaeten; M F Belin; P Giraudon; A Bernard
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40).

Authors:  J R Backstrom; G P Lim; M J Cullen; Z A Tökés
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

8.  Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

Authors:  Stefan Lorenzl; Noel Calingasan; Lichuan Yang; David S Albers; Shuei Shugama; Jason Gregorio; H W Krell; Jason Chirichigno; Tong Joh; M Flint Beal
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 9.  Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.

Authors:  Barry W Festoff; Zhiming Suo; Bruce A Citron
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  MMP-7 cleaves the NR1 NMDA receptor subunit and modifies NMDA receptor function.

Authors:  Arek Szklarczyk; Osefame Ewaleifoh; Jean-Claude Beique; Yue Wang; David Knorr; Norman Haughey; Tanya Malpica; Mark P Mattson; Richard Huganir; Katherine Conant
Journal:  FASEB J       Date:  2008-07-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.